Stock Groups

It could take up to 10 weeks to get product back in stores from affected facility

[ad_1]

An empty shelf at Target in San Antonio, Texas shows a lack of baby formula, on May 10, 2022.

Reuters| Reuters

The owner of a key baby formula manufacturing plant said Wednesday it is looking to restart its plant in as little as two weeks — but said it would take between six to eight weeks to get formula products back on store shelves once production gets going again.

This facility was shut down by Abbott LaboratoriesThe infant formula shortage has been caused by the closure of Similac, Alimentum, and EleCare’s Sturgis facility. It was temporarily closed down by the federal government in February as a result of a federal investigation into deaths of two infants, and illnesses reported among children who ingested certain baby formula products. The plant is still closed.

Abbott stated Wednesday that it can restart Sturgis’ site within two weeks if the Food and Drug Administration approves. Abbott indicated that product would not be available until six to eight weeks after the facility is restored to normal.

It stated that production would start first with EleCare, Alimentum, and metabolic formulas and then move on to Similac and the other formulas.

It can be as high as 43 percent of normal supplies of formula were out of stock in U.S. grocery stores in the first week of May, according to data from retail research group Datasembly. Washington has been urged to take action due to the shortage. According to Tuesday’s statement, FDA stated that they were expediting export documentation from foreign product to speed up the delivery of formula. They also grant case-by–case waivers in order to permit the sale “life-sustaining supplies” of metabolic and specialty formulas.

Abbott stated Wednesday that there is no proof linking the formulas and infants’ diseases. However, at least one pathogen has been linked to children’s diseases. Cronobacter Sakazakii was found in environmental testing as part of the FDA’s investigation, it was detected in “nonproduct contact areas of the facility and has not been linked to any known infant illness,” the agency said.

The statement stated, “In all four instances, the FDA/CDC and/or the state tested samples from the Abbott formula that the child used.” “In all four cases, all unopened containers tested negative.”

Abbott’s full statement can be viewed here here.

[ad_2]